ERBB2 and gastroesophageal junction adenocarcinoma: Numerous clinical studies have demonstrated the efficacy of RC48 in treating patients with either locally advanced or metastatic HER2-overexpressing gastric cancer, including adenocarcinoma of the gastroesophageal junction, following a minimum of two systemic chemotherapy courses (27–29).